Review Article
Antibody-Drug Conjugate in the Treatment of Pediatric AML and ALL: A Review
Zhe Liu,
Liyan Fan,
Xuchen Fan,
Shaoyan Hu,
Mi Zhou*
Issue:
Volume 10, Issue 1, February 2024
Pages:
1-10
Received:
11 December 2023
Accepted:
2 January 2024
Published:
11 January 2024
Abstract: Purpose: Antibody-drug conjugate has certain advantages in the treatment of childhood leukemia, which can improve the therapeutic effect and reduce toxic side effects. In this review, we try to collect all available human and pre-clinical data from 2021 to 2023 in this field. Methods: The search was done in PubMed database, using the following keywords: "Leukemia," "Inotuzumab ozogamicin," "Gemtuzumab ozogamicin," "Antibody drug conjugate," "Pediatric," "Children," "Childhood," In vitro studies, animal studies or clinical studies focusing solely on pharmacokinetics, pharmacoeconomics or safety were discarded. This review focuses on clinical outcomes including the assessment of complete response rate, adverse drug reactions and event free survival. Other clinical outcomes taken into account were adjunctive medications, relapse or motality. Results: Based on 16 included studies in this review, the vast majority of patients achieved hematologic remission with ADC therapy. The adverse reactions caused by ADC recorded in all studies include: neutropenia with fever, gastrointestinal symptoms, VOD, cytokine syndrome, infection, sepsis, gastrointestinal symptoms, hyperglycemia, hyperphosphatemia, anemia, thrombocytopenia, tumor lysis syndrome, liver function damage, altered mental state and abdominal swelling. Conclusion: Further studies are required to determine the optimal dose, duration, and the best formulation of ADC to prevent and/or manage chemotherapy-induced complications.
Abstract: Purpose: Antibody-drug conjugate has certain advantages in the treatment of childhood leukemia, which can improve the therapeutic effect and reduce toxic side effects. In this review, we try to collect all available human and pre-clinical data from 2021 to 2023 in this field. Methods: The search was done in PubMed database, using the following keyw...
Show More